PT-141 (Bremelanotide) in Adults 65 and Older: What the Evidence Actually Shows

What Bremelanotide Is and How It Works in the Brain

Bremelanotide is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It binds melanocortin receptors MC3R and MC4R in the central nervous system, primarily in hypothalamic regions tied to sexual arousal and motivation. This mechanism sets it apart from phosphodiesterase inhibitors, which act peripherally on vascular smooth muscle.

The FDA granted approval in June 2019 under the brand name Vyleesi, specifically for acquired, generalized HSDD in premenopausal women. The label explicitly excludes postmenopausal women and men, categories that encompass virtually the entire population aged 65 and older. FDA prescribing information for Vyleesi is publicly available through the FDA drug database.

The Melanocortin System and Sexual Function

MC4R signaling in the paraventricular nucleus of the hypothalamus drives appetitive sexual behavior in animal models and, based on clinical pharmacology studies, appears to do the same in humans. A 2014 review published in the Journal of Sexual Medicine outlined how melanocortin agonism produces pro-erectile and pro-arousal effects through pathways distinct from nitric oxide. See the melanocortin receptor review at PubMed.

Why Central Mechanisms Matter More With Age

Aging changes hypothalamic function substantially. Gonadotropin-releasing hormone pulse frequency declines, sex hormone binding globulin rises, and the density of hypothalamic MC4R may shift with declining estrogen and testosterone. These age-related neuroendocrine changes are documented across multiple endocrine society publications. A 2019 review in the Journal of Clinical Endocrinology and Metabolism covers age-related hypothalamic changes in detail.

Because bremelanotide acts centrally rather than peripherally, any age-related reduction in receptor density or downstream signaling could theoretically blunt efficacy. This has not been formally studied in patients 65 and older.

The RECONNECT Trial Data: Who Was Actually Studied

The key efficacy data for bremelanotide come from two parallel Phase 3 randomized controlled trials, RECONNECT-1 and RECONNECT-2, published in Obstetrics and Gynecology in 2019. Combined, these trials enrolled 1,247 premenopausal women. Mean age in the treatment groups was approximately 38 years. The primary RECONNECT publication is indexed at PubMed.

What RECONNECT Measured

The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm total score. At 24 weeks, bremelanotide 1.75 mg produced statistically significant improvements versus placebo on both endpoints (P<0.001 for each). The number needed to treat for a clinically meaningful response was approximately 8 to 9.

Who Was Excluded

RECONNECT required participants to be premenopausal. The upper age limit effectively excluded most women in their late 40s who were perimenopausal, let alone those 65 and older. No geriatric subgroup analysis was pre-specified. This is a meaningful data gap because HSDD is prevalent across the lifespan, with estimates suggesting 8 to 10 percent of women over 60 meet diagnostic criteria. Prevalence data for sexual dysfunction in older women are reviewed in this JAMA Internal Medicine cohort analysis.

Age-Related Physiology That Changes Bremelanotide's Risk Profile

Several physiological changes that accompany aging directly affect how bremelanotide behaves in the body. These are not theoretical concerns. Each interacts with known pharmacodynamic or pharmacokinetic properties of the drug.

Blood Pressure and Cardiovascular Risk

The most clinically significant safety signal in RECONNECT was transient blood pressure change. In the pooled safety data, bremelanotide produced mean decreases in systolic blood pressure of approximately 1.8 to 5.8 mmHg and diastolic blood pressure of 1.6 to 4.3 mmHg within 12 hours of dosing. In a subset of participants, decreases exceeded 20 mmHg systolic. This cardiovascular safety data appears in the RECONNECT safety supplement and is summarized in the FDA Medical Review Document.

Adults 65 and older have a substantially higher baseline prevalence of hypertension and are more likely to be on antihypertensive medications, including ACE inhibitors, calcium channel blockers, and alpha-blockers. The interaction between bremelanotide and antihypertensive agents has not been formally characterized in older populations. Baroreflex sensitivity also declines with age, meaning older adults may have a blunted compensatory heart rate response to acute blood pressure drops. Age-related baroreflex changes are discussed in this American Heart Association scientific statement.

Renal and Hepatic Clearance

Bremelanotide is eliminated via hepatic peptide hydrolysis and renal excretion. The FDA label notes that exposure increases approximately 1.5-fold in patients with severe renal impairment (GFR <30 mL/min per 1.73 m²), but no dose adjustment recommendation is provided, and use in end-stage renal disease has not been studied. The full prescribing information is available through FDA.

Renal function declines predictably with age. The MDRD and CKD-EPI equations both show that average estimated GFR falls by roughly 1 mL/min per 1.73 m² per year after age 40. A healthy 70-year-old may have an eGFR of 60 to 70 mL/min compared to 95 to 100 mL/min in a healthy 30-year-old, and many adults 65 and older have stage 3 CKD. CKD prevalence data by age are published by the CDC.

Polypharmacy

Adults 65 and older take an average of 5 to 9 prescription medications. Bremelanotide's drug interaction profile in this context is poorly characterized. The drug label notes no formal pharmacokinetic interaction studies with commonly used geriatric medications including statins, beta-blockers, or oral hypoglycemics. Polypharmacy prevalence in older adults is covered in this JAMA study.

Off-Label Use in Older Men and Postmenopausal Women

Bremelanotide has no approved indication in men or postmenopausal women. Off-label use in both groups is occurring in compounding pharmacy and telehealth settings, driven by patient and clinician interest in non-PDE5 mechanisms.

Evidence in Men

Early Phase 1 and Phase 2 studies with PT-141 in men with erectile dysfunction showed that intranasal administration produced erections in a dose-dependent fashion. A Phase 2 RCT published in the Journal of Sexual Medicine in 2008 found that intranasal PT-141 improved erectile function scores compared to placebo, though this route of administration was not advanced to Phase 3 due to blood pressure concerns. The 2008 PT-141 male ED trial is indexed at PubMed.

The subcutaneous formulation now approved as Vyleesi was not studied in men in Phase 3 trials. No RCT data exist specifically for men over 65. Older men also tend to have lower baseline testosterone, which may modulate melanocortin receptor sensitivity. Age-related testosterone decline is reviewed in this Journal of Clinical Endocrinology and Metabolism paper.

Evidence in Postmenopausal Women

HSDD is recognized as a significant quality-of-life issue in postmenopausal women. Flibanserin (Addyi) carries an FDA-approved indication only in premenopausal women as well, leaving postmenopausal HSDD without an approved pharmacological option in most cases. Several small studies have examined bremelanotide in postmenopausal women, with mixed results. A Phase 2 dose-ranging study that included postmenopausal participants found signals of efficacy but also a higher frequency of nausea and flushing compared to younger participants. That Phase 2 data is available in the PubMed record.

The 2023 Menopause Society (formerly NAMS) clinical practice guideline on sexual health acknowledges that evidence for bremelanotide in postmenopausal women is insufficient to support a firm recommendation, but does not prohibit consideration in individualized cases. The Menopause Society guideline is available through menopause.org.

Hormonal Context in Adults 65 and Older

The sexual function of adults 65 and older sits at the intersection of multiple declining hormonal axes. Estrogen in women has been near its nadir for years or decades. Testosterone in men falls at roughly 1 to 2 percent per year after age 30, and by 65, a substantial minority have clinically low levels. The Massachusetts Male Aging Study documented this trajectory across a cohort of 1,700 men, with data indexed at PubMed.

Does Testosterone Status Affect Bremelanotide Response?

Animal studies show that gonadal steroids modulate MC4R expression. Castration in rodents reduces melanocortin-induced sexual behavior, while testosterone replacement restores it. Whether this translates to a clinically meaningful interaction in older humans is unknown. No clinical trial has stratified bremelanotide response by baseline testosterone or estradiol level.

This is a real gap. A clinician considering bremelanotide in a 68-year-old man or woman should assess sex hormone status first. If testosterone is frankly low and undertreated, beginning testosterone replacement before or alongside bremelanotide may improve the probability of response. This is not protocol-level guidance; it is a clinical inference from the basic science.

Thyroid and Adrenal Function

Bremelanotide acts at MC3R as well as MC4R. MC3R is expressed in the adrenal gland and may modulate ACTH sensitivity. In older adults with subclinical adrenal insufficiency or those on chronic corticosteroids, this receptor crosstalk could have theoretical implications. No clinical studies have examined this interaction in any age group. MC3R biology is reviewed in this NIH-indexed endocrine pharmacology paper.

Adverse Effects Most Relevant to Geriatric Patients

The RECONNECT pooled safety population showed that the most frequent adverse events were nausea (40.1% bremelanotide vs. 17.5% placebo), flushing (20.4% vs. 3.7%), and injection site reactions (13.2% vs. 4.7%). Hyperpigmentation of the face, breasts, and gingiva was seen in some participants with extended use, driven by off-target MC1R activation. These safety data are from the FDA Medical Review, available through FDA.gov.

Nausea in Older Adults

Nausea at 40 percent incidence is not a minor issue in a population that may already be managing gastroparesis, delayed gastric emptying, or antiemetic drug load. Bremelanotide-associated nausea peaks within 60 to 90 minutes of injection and typically resolves within 4 hours, but this window coincides with the intended period of sexual activity. Older adults with vestibular dysfunction may find nausea more disabling than younger counterparts.

Hyperpigmentation With Chronic Use

In the open-label extension of RECONNECT, 1 percent of participants developed focal hyperpigmentation with repeated dosing over 52 weeks. Older adults with existing solar lentigines or actinic damage may find new hyperpigmented lesions harder to distinguish from potentially malignant lesions, requiring dermatologic follow-up. The 52-week open-label extension data are indexed at PubMed.

Falls Risk

An acute transient blood pressure drop in a 70-year-old who also takes tamsulosin or a diuretic creates measurable falls risk. Falls are the leading cause of injury-related death in adults 65 and older in the United States. Any medication that produces predictable hemodynamic changes in this population requires explicit conversation about timing, setting, and companion awareness. CDC fall data are available at cdc.gov.

A Clinical Decision Framework for Bremelanotide in Patients 65 and Older

No published protocol governs bremelanotide use specifically in older adults. The following framework synthesizes FDA label requirements, age-related pharmacology, and general geriatric prescribing principles. It is intended as a starting point for discussion between patient and clinician, not as a substitute for individualized assessment.

Step 1: Confirm the Diagnosis

HSDD requires that low sexual desire causes personal distress. Rule out relationship factors, undiagnosed depression, thyroid dysfunction, and medication-induced sexual dysfunction (SSRIs, beta-blockers, antiandrogens) before initiating any pharmacotherapy.

Step 2: Assess Cardiovascular and Renal Baseline

Obtain a resting blood pressure. If systolic blood pressure is <90 mmHg at baseline, bremelanotide is contraindicated per FDA label. Estimate GFR using CKD-EPI. If GFR <30 mL/min per 1.73 m², the drug has not been studied and use should be approached with explicit caution and close monitoring.

Step 3: Review the Medication List

Check for antihypertensives (particularly alpha-blockers, nitrates, and calcium channel blockers), diuretics, and any QT-prolonging agents. Discuss fall risk explicitly. Note that the FDA label contraindicates bremelanotide with naltrexone-containing products.

Step 4: Sex Hormone Assessment

Measure total and free testosterone, estradiol, FSH, and LH. If testosterone is below the lower limit of normal for age and sex and the patient is not already on hormone replacement, address that deficit as a first-line step. Testosterone measurement and normal ranges in older men are covered in the Endocrine Society clinical practice guideline.

Step 5: Start Low, Monitor Closely

The approved dose is 1.75 mg subcutaneous. No lower dose is currently commercially available, but some compounding pharmacies offer 0.875 mg formulations. If a lower dose is used, it is entirely off-label and lacks pharmacokinetic bridging data. Have the patient self-administer the first dose at home, not during a planned encounter, so any blood pressure or nausea response can be assessed without distress.

What Clinicians and Researchers Have Said

The Endocrine Society's 2020 statement on female sexual dysfunction notes: "Bremelanotide is effective for HSDD in premenopausal women, but data in postmenopausal women and men are insufficient to guide clinical practice." The Endocrine Society statement is accessible through academic.oup.com.

Dr. Rosemary Basson, a key contributor to the DSM-5 revisions on female sexual dysfunction, has written that "sexual desire in older women is context-dependent to a greater degree than in younger women, and pharmacological interventions have to be matched to a nuanced biopsychosocial assessment." Her framework work is cited in this NEJM review of female sexual dysfunction.

These statements reinforce that bremelanotide is not a standalone solution in older adults. The drug works centrally on motivation and desire, but age-related sexual concerns often involve partner health, relationship context, chronic pain, and body image in ways that no single molecule addresses.

The Research Gap: What Studies Are Needed

The absence of geriatric-specific data is not unique to bremelanotide. Most sexual medicine trials systematically exclude older adults, creating a literature that underpowers guidance for the population most likely to experience multimorbidity-related sexual dysfunction. A 2021 BMJ analysis of age exclusion in clinical trials documents this pattern across therapeutic areas.

A dedicated Phase 2 trial of bremelanotide in adults 60 and older, stratified by hormone status and comorbidity burden, would directly inform clinical practice. Secondary outcomes should include falls, blood pressure monitoring at 2 and 6 hours post-dose, and validated geriatric quality-of-life instruments beyond standard sexual function scales.

Until that data exists, prescribers rely on extrapolation from younger cohorts, basic pharmacology, and clinical judgment. That is an acceptable starting point. It is not a finishing point.